



THE
BLADDER CANCER
COMPANY

Photocure ASA: Transactions made under share buyback program

Oslo, 5 January 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on 19 December 2024 of the launch of Photocure's program to repurchase up to 300,000 of its own shares for a total maximum amount of NOK 30 million during the period from 19 December 2024, until no later than 31 March 2025, pursuant to an agreement with DNB Markets.

For the period from and including 19 December 2024, through 3 January 2025, the Company purchased a total of 150,802 shares at an average price of NOK 62.43 per share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please find below the transaction overview:

Date	Aggregated daily volume (#shares)	Weighted average share price per day (NOK)	Total daily transaction value (NOK)
19.12.2024	23,776	61.43	1,460,610
20.12.2024	21,764	62.95	1,370,150
23.12.2024	21,170	64.17	1,358,511
27.12.2024	16,547	64.29	1,063,742
30.12.2024	21,564	63.50	1,369,286
02.01.2025	22,401	61.77	1,383,629
03.01.2025	23,580	59.73	1,408,325
Total for the period	#shares	Weighted average share price (NOK)	Total transaction value (NOK)
	150,802	62.43	9,414,253

No previously disclosed buybacks under the program.

Accumulated under the buyback program	#shares	Weighted average share price (NOK)	Total transaction value (NOK)
	150,802	62.43	9,414,253

The issuer's holding of own shares:

Following the completion of the above transactions, Photocure owns a total of 165,924 of own shares (including 15,122 shares owned prior to the launch of the buyback program), corresponding to 0.61% of Photocure's share capital.

Appendix:

An overview of all transactions made under the buyback program that have been carried out during the

above-mentioned time period is attached to this report and available at www.newsweb.no.

For further information, please contact:

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com and www.cysview.com. All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is made public by Photocure ASA pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.